Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS), Viridian Therapeutics (VRDN) and Atricure (ATRC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Glaukos (GKOS – Research Report), Viridian Therapeutics (VRDN – Research Report) and Atricure (ATRC – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Glaukos (GKOS)
Needham analyst David Saxon reiterated a Buy rating on Glaukos today and set a price target of $127.00. The company’s shares closed last Tuesday at $106.64.
According to TipRanks.com, Saxon is a 1-star analyst with an average return of
Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $141.78, implying a 29.2% upside from current levels. In a report issued on February 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $160.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Viridian Therapeutics (VRDN)
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $47.00. The company’s shares closed last Tuesday at $28.29.
According to TipRanks.com, Chico is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $41.86 average price target, a 50.0% upside from current levels. In a report issued on February 4, Needham also maintained a Buy rating on the stock with a $42.00 price target.
Atricure (ATRC)
In a report released yesterday, William Plovanic from Canaccord Genuity reiterated a Buy rating on Atricure, with a price target of $53.00. The company’s shares closed last Tuesday at $32.97.
According to TipRanks.com, Plovanic is a 3-star analyst with an average return of
Currently, the analyst consensus on Atricure is a Moderate Buy with an average price target of $48.33, representing a 48.0% upside. In a report issued on February 3, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.
